f-Star

44 articles with f-Star

• F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid TumorsStudy is Evaluating Intravenously Administered Novel STING Agonist Alone and In Combination with Atezolizumab

  7/26/2021

  F-star Therapeutics, Inc. is providing an interim update on the first-in-human dose-escalation study of SB 11285, a second generation STING agonist.

• F-star Therapeutics to Present at Upcoming Investor ConferencesCompany Leadership will Speak at Ladenburg Thalmann 2021 Healthcare Conference and the William Blair 2021 Biotech Focus Conference

  7/9/2021

  F-star Therapeutics, Inc. today announced that the company will participate in two virtual investor conference events next week. Details are as follows: Ladenburg Thalmann Healthcare Conference 2021

• F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors

  7/8/2021

  F-star Therapeutics, Inc. today announced that it has entered into an exclusive licensing agreement with AstraZeneca plc.

• F-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021

  5/10/2021

  F-star Therapeutics, Inc.  (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host an investor conference call and webcast on Monday, May 17, 2021 at 9:00 a.m. EST to discuss financial results for the quarter ending March 31, 2021 and provide a corporate update.

• F-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common Stock

  5/7/2021

  F-star Therapeutics, Inc. (Nasdaq: FSTX) (the “Company” or “F-star”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced the pricing of its underwritten public offering of 9,285,715 shares of its common stock at a public offering price of $7.00 per share.

• Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy

  4/19/2021

  F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285,

• F-star Therapeutics Reports Full-Year 2020 Financial Results and Provides Corporate UpdateCompany to Host Conference Call Today at 9 a.m. EDT

  3/29/2021

  F-star Therapeutics, Inc.  (NASDAQ: FSTX) , a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announces 2020 full-year financial results and provides corporate update. 2020 was a year of transformation for F-star.

• F-star Therapeutics to Host Full-Year 2020 Investor Call and Provide Corporate Update on March 29, 2021

  3/16/2021

  F-star Therapeutics, Inc.  (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that it will host a full year 2020 investor conference call and webcast on Monday, March 29, 2021 at 9:00 a.m. EDT.

• F-star Therapeutics to Present at SITC 2020 Virtual Annual Meeting

  10/22/2020

   F-star Therapeutics Ltd., a clinical-stage immuno-oncology company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2 ™) antibodies, today announced that it will present two posters at the Society for Immunotherapy of Cancer's (SITC)

• F-star Therapeutics to Participate in BTIG Virtual Biotechnology Conference

  8/5/2020

  F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb 2 ™) antibodies, today announces that Eliot Forster, Chief Executive Officer, will participate in a Fireside Chat at the BTIG Virtual Biotechnology Conference on Monday August 10, 2020. Event : F-star

• F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting

  6/22/2020

  F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovat

• F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research

  4/9/2020

  F-star Therapeutics Ltd., today announces the publication of preclinical data on the potent anti-tumor activity of FS120, a first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40

• F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA

  6/18/2019

  F-star Therapeutics Ltd. announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer, succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.

• F-star appoints Dr Louis Kayitalire as Chief Medical Officer

  6/10/2019

  F-star, a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, announces the appointment of Louis Kayitalire, MD, as Chief Medical Officer, which will be effective on 17 June 2019.

• F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting

  3/25/2019

  Three poster presentations highlighting the synergistic benefits of the tetravalent bispecific (mAb2™) format compared to monospecific agents either alone or in combination

• F-star to Disclose Targets and Preclinical Data on New Agonist Bispecific Antibody Programmes

  11/1/2018

  Developed to address current patient needs that are not well-served by checkpoint monotherapies or combinations of monotherapies

• 

  BioSpace Movers and Shakers - Oct. 22

  10/22/2018

  Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes.

• F-star Appoints Dr Eliot Forster as Chief Executive Officer

  10/15/2018

  F-star today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.

• F-star Appoints Nessan Bermingham as Chairman of its Board of Directors

  9/10/2018

  Nessan succeeds John Edwards who has been F-star’s Chairman for seven years and will remain as a non-executive director.

• F-star Announces the Achievement of a Clinical Milestone in its Immuno-Oncology Collaboration with Merck

  7/24/2018

  Enrolment and dose escalation in FS118 Phase I clinical study trigger milestone payment